Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

NCT03798054 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

878

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine/Lixisenatide (HOE901/AVE0010)
DRUG: Insulin glargine (HOE901)
DRUG: Lixisenatide (AVE0010)
DRUG: Metformin
DRUG: SGLT2 inhibitor

Sponsor

Sanofi